Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 09:02 PM UTC

Segments 12-15 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, the first large late-stage study of a custom cancer therapy using mRNA technology. Patients receiving the treatment with Keytruda went longer without cancer recurrence, and Moderna shares closed 177% higher. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 08:57 PM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, showing improved recurrence-free survival when combined with Keytruda. This is a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 08:52 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, with patients receiving the custom treatment plus Keytruda showing longer progression-free survival than those on Keytruda alone. This positive clinical result is a material positive catalyst for Moderna, supporting a BUY operation.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 08:47 PM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, causing a 177% stock surge. This is a material positive catalyst indicating improved expected fundamentals.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 08:42 PM UTC

Segments 13-16 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, indicating a strong positive catalyst.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 08:37 PM UTC

Moderna and Merck reported positive Phase 3 results for their personalized cancer treatment, showing longer progression-free survival compared to Keytruda alone. This is a material positive catalyst for Moderna, supporting a BUY operation.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 08:32 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, with patients receiving the custom treatment plus Keytruda going longer without cancer recurrence, and Moderna shares surged 177% on the news, indicating a material positive catalyst.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 08:27 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, with patients receiving the custom shot plus Keytruda showing longer progression-free survival than those on Keytruda alone. This is a material positive catalyst for Moderna, and the stock surged 177% on the news.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 08:22 PM UTC

Segments 13-16 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, their largest one-day gain on record. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 08:17 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, showing improved recurrence-free survival when combined with Keytruda, leading to a 177% stock surge. This is a material positive catalyst for Moderna.